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ABSTRACT
Introduction: Diabetic nephropathy (DN) is a
progressive kidney disease resulting as a com-
plication of diabetes mellitus. This study eval-
uated the disease progression and economic
burden of DN among commercially insured
patients with type 2 diabetes in the USA.
Methods: The research design was a retrospec-
tive observational study based on healthcare
claims data. The Truven MarketScan Databases
(2004–2014) were queried for adults with type 2
diabetes with at least one urine albumin test
(index, randomly selected) after diagnosis
and at least one test after the index. On the
basis of the index test, patients were classified
into normoalbuminuria, microalbuminuria, or
macroalbuminuria groups. Nephropathy-re-
lated treatment use was measured in the
6 months after the index, disease progression
was assessed from the index to the end of data
availability, and annual all-cause and
nephropathy-related costs and healthcare
resource use (HRU) were assessed up to 2 years
from the index. Outcomes were compared
between any two groups, controlling for base-
line demographics.
Results: A total of 23,235 patients were identi-
fied and classified into normoalbuminuria
(N = 18,409), microalbuminuria (N = 3863), or
macroalbuminuria (N = 963) groups. Patients
with albuminuria were more likely to be older,
male, and have a higher burden of baseline
comorbidities and HRU. Within 6 months fol-
lowing the index, 12–20% of patients with
albuminuria were not treated with any relevant
recommended treatment. Compared to the
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normoalbuminuria group, patients with
macroalbuminuria had a significantly greater
risk of disease progression (hazard ratio
[HR] = 1.44), and both albuminuria groups were
more likely to require dialysis (HR = 4.23 and
40.14 for micro- and macroalbuminuria,
respectively; all p\0.05). Annual all-cause
(2016 US dollars, $3580 and $12,830 higher for
micro- and macroalbuminuria vs. normoalbu-
minuria, respectively) and nephropathy-related
($362 and $3716) costs increased significantly
with increasing nephropathy severity, consis-
tent with the trend in increased HRU.
Conclusions: Diabetic nephropathy may be
undertreated or inappropriately treated. It was
also associated with significantly higher costs,
HRU, and risk of disease progression among
commercially insured patients with type 2 dia-
betes in the USA.
Funding: Takeda Development Center Americ-
as, Inc.
Keywords: Albuminuria; Heath care costs;
Microalbuminuria; Type 2 diabetes
INTRODUCTION
Diabetic nephropathy (DN) is a progressive
kidney disease caused by damage to the small
blood vessels in the kidney’s glomeruli [1],
resulting as a complication of diabetes melli-
tus (DM) [2]. DN affects up to 40% of patients
with diabetes [3], with a total estimated
prevalence of approximately 6.9 million peo-
ple in the USA [4]. Diabetic nephropathy is a
leading cause of end-stage renal disease
(ESRD) and greatly increases the risk of all-
cause mortality, cardiovascular-related mor-
bidity and mortality, and kidney failure
among patients with diabetes [5, 6]. This dis-
ease is usually detected by the presence of
albuminuria, which is identified on the basis
of urine albumin laboratory tests [3, 7, 8], e.g.,
urinary albumin excretion rate or albu-
min-to-creatinine ratio (ACR).
Treatment strategies for patients with mild
to severe DN aim to prevent further renal
function decline and delay disease progression
via glycemic and blood pressure control, and
through inhibition of the renin–an-
giotensin–aldosterone system (RAAS) [3, 7].
Treatment regimens commonly include
RAAS-blocking agents such as angiotensin-con-
verting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARB). How-
ever, these therapies are considered to be inad-
equate for the treatment of diabetic
nephropathy, as they do not reverse the disease
[9, 10]. Treatment combinations, such as
dual-RAAS blockade with ACE inhibitors and
ARBs, have been considered, but they are asso-
ciated with adverse events (e.g., hyperkalemia
and acute kidney injury); thus, these treatment
combinations are not recommended, and are
contraindicated in patients with renal impair-
ment [8, 11]. Finally, even with treatment with
currently available therapies, many patients
with diabetic nephropathy nevertheless pro-
gress to ESRD, requiring dialysis while kidney
transplant is considered [3].
As a result of the increased morbidity and
mortality associated with diabetic nephropathy,
patients with uncontrolled disease face severe
economic burden, with estimated average
annual healthcare costs ranging from $8000 to
$43,000 [12]. Patients with diabetic nephropa-
thy, especially those with severe stages of
nephropathy such as chronic kidney disease
and ESRD [12–15], incur higher economic bur-
den compared to those without renal impair-
ment [16–18]. In addition, patients who
progress to severe stages of kidney disease
experience higher rates of all-cause hospitaliza-
tion and healthcare resource utilization (HRU)
[13], and patients’ incremental costs associated
with the progression of chronic kidney disease
are significantly higher than those of patients
without renal impairment [12, 15].
Several prior studies have assessed the eco-
nomic burden of diabetic nephropathy using
various definitions of the condition. Nichols
et al. assessed the incremental healthcare costs
associated with progression to microalbumin-
uria, macroalbuminuria, and ESRD among
patients enrolled in a US region-specific health
maintenance organization with both type 2
diabetes mellitus (T2DM) and hypertension
[18], which may not adequately represent the
overall US patient population with DN. Further,
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medical costs were estimated on the basis of the
multiplicative product of ‘‘standard’’ visit costs
and frequency of healthcare visits, rather than
the observed reimbursement costs. Although
there has been some evidence published on UK
patients [19], there is currently limited
US-specific information on disease progression
and the economic burden associated with
microalbuminuria or macroalbuminuria among
patients with T2DM.
To address this knowledge gap, the current
study evaluated real-world disease progression
and the associated economic burden, including
all-cause and nephropathy-related HRU and
costs, among commercially insured USA-based




The data for this study were derived from the
Truven Health Analytics MarketScan Data-
bases (Jan 1, 2004–Dec 31, 2014). The Mar-
ketScan Commercial and Medicare
Supplemental claims databases represent
approximately 25 million individuals (em-
ployees and their dependents, as well as
Medicare-eligible retirees) annually covered by
over 130 health plans and self-insured
employers. The databases contain patient
demographics, enrollment history, claims for
inpatient and outpatient medical services, and
claims for prescription pharmaceuticals. The
MarketScan Lab Database contains laboratory
test results for a subset of the individuals
(approximately 1 million patients) covered in
the Commercial and Medicare Supplemental
databases, capturing lab tests ordered in offi-
ce-based practices.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. All patient data were
de-identified and complied with the patient
confidentiality requirements of the Health
Insurance Portability and Accountability Act.
No ethical approval was required.
Study Population and Subgroups
The study population included patients with
type 2 diabetes who were at least 18 years old
and had at least two urine albumin tests (24-h
collection or ACR after the first observed type 2
diabetes diagnosis [International Classification
of Diseases, 9th revision, Clinical Modification
(ICD-9-CM) codes 250.x0 or 250.x2)]. From this
population, a subset of patients with at least one
eligible urine albumin test meeting the follow-
ing criteria were identified: (1) at least one
additional urine albumin test following the test
date; and (2) continuous enrollment in a health
plan for at least 12 months before the test date
and at least 6 months following the test date
and through at least one subsequent urine
albumin test. Patients with ESRD (ICD-9-CM
codes 403.x1, 404.x2, 404.x3, 585.5, or 585.6)
during the 12-month period prior to the test
date were excluded.
For each patient, the presence of microalbu-
minuria or macroalbuminuria was evaluated on
the basis of a randomly selected eligible urine
albumin test (index test) and used to classify the
patient into one of three groups: (1) the nor-
moalbuminuria group (urinary albumin excre-
tion of less than 30 mg/24 h or an ACR of less
than 30 lg/mg); (2) the microalbuminuria
group (urinary albumin excretion of
30–300 mg/24 h or an ACR of 30–300 lg/mg);
and (3) the macroalbuminuria group (urinary
albumin excretion of greater than 300 mg/24 h
or an ACR of greater than 300 lg/mg). The date
of the index test was defined as the index date.
Study Measures and Outcomes
Patient demographics, disease characteristics,
baseline nephropathy- and diabetes-related
treatment use, and all-cause HRU and costs were
measured during the 12-month period prior to
the index date (baseline). The overall comor-
bidity burden during the baseline period was
measured using the Charlson comorbidity
index (CCI) [20].
Nephropathy-related treatment use was
assessed in the 6 months following the index
date, and included ACE inhibitors, ARBs,
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diuretics, calcium channel blockers, and other
antihypertensive agents, consistent with a prior
publication [7]. Disease progression was assessed
from the index date until the end of continuous
eligibility, end of data availability, or inpatient
mortality, whichever came first. Data captured
included time to progression to a more severe
stage of diabetic nephropathy and time to dial-
ysis/hemodialysis. For the normoalbuminuria
group, disease progression was defined as the
presence of a urine albumin test indicating
microalbuminuria or macroalbuminuria, a diag-
nosis of ESRD, or a dialysis or renal transplanta-
tion procedure. For the microalbuminuria group,
disease progression was defined as the presence
of a urine albumin test indicating macroalbu-
minuria, a diagnosis of ESRD, or a dialysis or renal
transplantation procedure. For the macroalbu-
minuria group, disease progression was defined
as the presence of a diagnosis of ESRD or a dialysis
or renal transplantation procedure.
HRU and healthcare costs were assessed from
the index date until 2 years from the index date,
the end of continuous eligibility, end of data
availability, or patient mortality, whichever
occurred first. HRU included all-cause and
nephropathy-related inpatient, emergency
room (ER), outpatient, and other medical visits.
Healthcare costs were evaluated from a third-
party payer perspective and included all-cause
and nephropathy-related healthcare costs
resulting from medical services (inpatient, ER,
outpatient, and other medical services) and
pharmacy prescriptions. Nephropathy-related
HRU and costs were defined as medical services
and costs associated with a diagnosis of diabetic
nephropathy or kidney disease (ICD-9-CM
codes 249.4, 250.4, 583.81, 403.xx, 404.xx, or
585.xx), or a procedure for dialysis/hemodialy-
sis or renal transplantation. Costs were con-
verted to 2016 US dollars using the Consumer
Price Index medical care component.
Statistical Analyses and Software
Baseline patient demographics and clinical
characteristics were compared across groups
using Wilcoxon rank-sum tests for continuous
variables and Chi-square tests for categorical
variables. Means and standard deviations were
reported. Proportions of patients using
nephropathy-related treatments during the
6 months following the index date were com-
pared using multivariable logistic regression
models, and adjusted odds ratios (ORs) with
p values were reported. Time to progression to a
more severe disease stage and time to dialysis/
hemodialysis were evaluated using Kaplan–Me-
ier analyses, and compared between study groups
using log-rank tests. Cox proportional hazard
models were used to further compare any two
study groups with adjustment for baseline
patient demographics, and adjusted hazard
ratios (HRs) with 95% confidence intervals (CI)
and p values were reported. Incidence rates of
each type of healthcare visit per patient per year
were described and compared using multivari-
able Poisson regression models, and the adjusted
incidence rate ratios (IRRs) with 95% CIs and
p values were reported. To account for over-dis-
persion, 95% CIs and p values were estimated
using a nonparametric bootstrap resampling
technique with 499 iterations. Annual costs in
each cost category were described and compared
using Wilcoxon rank-sum tests. Adjusted incre-
mental cost differences were estimated using
multivariable generalized linear models. For cost
components with more than 5% zero values, a
Tweedie distribution with an exponent of 1.67
was employed [21], and for all other compo-
nents, a gamma distribution and a log link were
used. All multivariable models were adjusted for
baseline patient demographics, including age at
index date, sex, region of residence, and insur-
ance type. Baseline patient characteristics and
outcomes were compared pairwise between any
two of the three study groups.
Statistical analyses were performed using
SAS, version 9.3 (Cary, NC, USA). A p value




A total of 23,235 patients met the sample
selection criteria and were included in the
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analysis. Of these, 18,409 (79%) patients were
classified into the normoalbuminuria group,
3863 (17%) into the microalbuminuria group,
and 963 (4%) into the macroalbuminuria group
(Fig. 1). Baseline demographics such as age, sex,
and residential region were different between
the three groups (Table 1); patients with
microalbuminuria or macroalbuminuria were
slightly older (mean age [SD] = 54.9 [10.2] and
56 [10.3] years, respectively) and had more men
(60% and 63%) than patients within the nor-
moalbuminuria group (mean age [SD] = 54.3
[9.6] years, 53% male).
Patients with more severe nephropathy dis-
played exacerbated clinical characteristics and
higher HRU and costs at baseline. The time
from the first observed type 2 diabetes diagnosis
in the database to the index date differed
between groups, with the macroalbuminuria
group having the longest time since diagnosis
(mean [SD] = 44.0 [30.5] months), followed by
the microalbuminuria (40.5 [27.9] months) and
normoalbuminuria (37.8 [26.6] months;
p\0.05 all comparisons) groups (Table 1). A
significantly higher comorbidity burden was
also observed in patients with microalbumin-
uria (CCI [SD] = 1.9 [1.4]) and macroalbumin-
uria (2.5 [1.7]) compared with the
normoalbuminuria group (1.6 [1.1]; all
p\0.05). With the exception of outpatient
services, where 99% of patients in each group
had at least one visit, patients with diabetic
nephropathy experienced significantly higher
rates of all-cause HRU during the baseline per-
iod compared to those with normoalbuminuria
(p\0.05 all comparisons), as well as higher
Fig. 1 Selection of study sample. ESRD end-stage renal disease, N number
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Table 1 Patient baseline and clinical characteristics






N5 18,409 N5 3863 N5 963
Age at index date
(years), mean ± SD
54.3 ± 9.6 54.9 ± 10.2 56.0 ± 10.3 § 
Male, n (%) 9836 (53%) 2310 (60%) 602 (63%) * §
Region, n (%)
Northeast 3577 (19%) 686 (18%) 180 (19%) *
North-Central 4687 (25%) 1029 (27%) 289 (30%) § 
South 7666 (42%) 1687 (44%) 378 (39%) * 
West 2475 (13%) 461 (12%) 116 (12%) *
Insurance plan type, n (%)
Preferred provider
organization
13,833 (75%) 2856 (74%) 711 (74%)
Non-capitated
point-of-service
1421 (8%) 250 (6%) 39 (4%) * § 
Exclusive provider
organization
911 (5%) 191 (5%) 52 (5%)
Comprehensive
traditional plan
1597 (9%) 434 (11%) 136 (14%) * § 




the database to the
index date (months),
mean ± SD
37.8 ± 26.6 40.5 ± 27.9 44.0 ± 30.5 * § 
Index urine albumin test characteristics
24-h urine albumin (mg)
n (%) 208 (1%) 57 (1%) 24 (2%)
Mean ± SD 7.5 ± 7.1 97.9 ± 73.5 2289.4 ± 2044.7 * § 
Median [min, max] 7.2 [0.0, 29.1] 73.0 [30.0, 281.0] 1519.5 [315.0,
7140.2]
Albumin/creatinine ratio (lg/mg)
n (%) 18,201 (99%) 3806 (99%) 939 (98%)
Mean ± SD 7.6 ± 6.5 88.6 ± 62.7 3439.6 ± 11,630.7 * § 
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Table 1 continued






N5 18,409 N5 3863 N5 963
Median [min, max] 6.0 [0.0, 29.8] 64.5 [30.0, 297.0] 734.0 [300.4,
90,000.0]
CCI, mean ± SD 1.6 ± 1.1 1.9 ± 1.4 2.5 ± 1.7 * § 
Disease-speciﬁc comorbidities, n (%)
Neuropathy 2355 (13%) 618 (16%) 218 (23%) * § 
Ischemic heart disease 2191 (12%) 602 (16%) 192 (20%) * § 
Retinopathy 2004 (11%) 593 (15%) 251 (26%) * § 
Anemia 1358 (7%) 356 (9%) 155 (16%) * § 
Depression 1198 (7%) 219 (6%) 51 (5%)
Cerebrovascular
disease
852 (5%) 255 (7%) 102 (11%) * § 
Heart failure 370 (2%) 159 (4%) 60 (6%) * § 
Ketoacidosis 150 (1%) 37 (1%) 22 (2%) § 
Hyperkalemia 111 (1%) 55 (1%) 23 (2%) * § 
High parathyroid
hormone level
106 (1%) 33 (1%) 22 (2%) * § 
High phosphorus level 16 (\1%) 5 (\1%) 3 (\1%)
Disease-speciﬁc treatments, n (%)
Nephropathy-related
treatments
12,726 (69%) 3032 (78%) 830 (86%) * § 
ACE inhibitor 6199 (34%) 1548 (40%) 427 (44%) * § 
Diuretic 3276 (18%) 850 (22%) 339 (35%) * § 
Calcium channel
blocker
2330 (13%) 811 (21%) 296 (31%) * § 




4661 (25%) 1132 (29%) 369 (38%) * § 
Diabetic treatments,
n (%)
15,177 (82%) 3363 (87%) 852 (88%) * §
Metformin 11,548 (63%) 2532 (66%) 510 (53%) * § 
Sulfonylureas 4293 (23%) 1125 (29%) 314 (33%) * § 
Insulin 3915 (21%) 1179 (31%) 459 (48%) * § 
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all-cause healthcare costs (p\0.05, all compar-
isons) (Table 1).
Nephropathy-Related Treatment Use
and Disease Progression During
the Follow-up Period
During the 6 months following the index date,
nephropathy-related treatments were used by
68% with normal urine albumin levels, 81% of
patients with microalbuminuria, and 88% of
patients with macroalbuminuria (Table S1).
ACE inhibitors were the most commonly used
treatment for nephropathy (32%, 41%, and
43% for the normoalbuminuria, microalbu-
minuria, and macroalbuminuria groups,
respectively). Both ACE inhibitors and ARBs
were used by 3% of patients with
Table 1 continued






N5 18,409 N5 3863 N5 963
DPP4 inhibitor 1756 (10%) 438 (11%) 111 (12%) * §
GLP1-based therapy 1279 (7%) 293 (8%) 72 (7%)
SGLT2 inhibitor 3 (\1%) 0 (0%) 0 (0%)
Other antidiabetic
agents
3847 (21%) 911 (24%) 259 (27%) * § 
All-cause healthcare resource utilization
Patients with C1 visit, n (%)
Inpatient admissions 1490 (8%) 453 (12%) 169 (18%) * § 
ER services 4150 (23%) 984 (25%) 263 (27%) * §
Outpatient services 18,226 (99%) 3817 (99%) 952 (99%)
Other 10,073 (55%) 2186 (57%) 610 (63%) * § 
Number of visits per patient, mean ± SD
Inpatient admissions 0.1 ± 0.4 0.2 ± 0.5 0.2 ± 0.6 * § 
Inpatient days 0.5 ± 2.9 0.8 ± 3.4 1.4 ± 4.5 * § 
ER services 0.4 ± 1.2 0.5 ± 1.4 0.6 ± 2.0 * §
Outpatient services 12.9 ± 12.6 12.9 ± 12.4 14.0 ± 12.4 § 
Other 2.0 ± 4.1 2.5 ± 4.9 3.5 ± 6.7 * § 
All-cause healthcare costs (2016 USD), mean ± SD
Total healthcare costs 10,602.7 ± 19,847.4 12,882.6 ± 25,539.6 15,849.0 ± 23,728.3 * § 
Total medical costs 7108.4 ± 18,682.0 9018.6 ± 24,305.0 11,184.5 ± 21,995.8 * § 
Total pharmaceutical
costs
3494.3 ± 4869.1 3864.0 ± 5130.1 4664.5 ± 6426.0 * § 
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, CCI Charlson comorbidity index,
DPP4 dipeptidyl peptidase 4, ER emergency room, GLP1 glucagon-like peptide-1, N number, SD standard deviation,
SGLT2 sodium-glucose cotransporter 2, USD United States dollars
* p\0.05 for [A] vs. [B]; § p\0.05 for [A] vs. [C];  p\0.05 for [B] vs. [C]
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microalbuminuria and 6% of patients with
macroalbuminuria.
During the follow-up period, patients with
microalbuminuria or macroalbuminuria had a
significantly greater risk of progression to a
more severe disease stage compared to patients
in the normoalbuminuria group (HRs
[CI] = 1.31 [1.08, 1.60] and 1.44 [1.21, 1.72],
respectively; both p\0.05) (Fig. 2a). Specifi-
cally, the 5-year disease progression rates were
15%, 19%, and 31% for the normoalbuminuria,
microalbuminuria, and macroalbuminuria
groups, respectively. Patients with microalbu-
minuria and macroalbuminuria were at signifi-
cantly higher risk of receiving dialysis/
hemodialysis compared to patients with nor-
moalbuminuria (HRs [CI] = 4.23 [2.45, 7.30]
and 40.14 [25.33, 63.60], respectively; both
p\0.001) (Fig. 2b). The 5-year dialysis rates
were 0.3% among patients with normal albu-
min levels, 2% among those with microalbu-
minuria, and 18% among those with
macroalbuminuria.
Annual All-Cause
and Nephropathy-Related HRU During
the Follow-up Period
The annual frequency of all-cause healthcare
visits rose significantly with the increasing
severity of the patient’s nephropathy, a trend
that was consistent across inpatient, outpatient,
ER, and other medical services visits (p\0.05 in
all pairwise adjusted IRR comparisons) (Table 2).
The microalbuminuria group experienced sig-
nificantly higher utilization rates of each type of
all-cause medical service in comparison with
the normoalbuminuria group, particularly
inpatient admissions (adjusted IRR [CI] = 1.51
[1.37, 1.65]; p\0.05 all adjusted IRR compar-
isons) (Table 2). Furthermore, the macroalbu-
minuria group experienced particularly
heightened average annual incidence rates of
all-cause inpatient admissions in comparison
with the microalbuminuria and normoalbu-
minuria groups (adjusted IRRs [CI] of 1.78 [1.50,
2.09] and 2.70 [2.34, 3.16], respectively; both
p\0.05). A similar trend was observed in
healthcare visits related to nephropathy, with
an increased magnitude of difference between
groups. In comparison with the normoalbu-
minuria group, the microalbuminuria group
had significantly higher incidence rates of
nephropathy-related inpatient (adjusted IRR
[CI] = 2.94 [2.21, 3.88]), ER (4.70 [3.09, 7.76]),
outpatient (3.77 [3.16, 4.48]), and other medical
service visits (6.26 [2.43, 19.46], all p\0.05)
(Table 2). Additionally, in comparison with
both the microalbuminuria and normoalbu-
minuria groups, patients with macroalbumin-
uria had significantly higher incidence rates of
nephropathy-related inpatient (adjusted IRRs
[CI] = 5.24 [3.91, 7.09] and 16.53 [12.14, 21.87],
respectively), ER (4.03 [2.49, 6.46] and 18.96
[11.79, 29.88]), outpatient (4.83 [3.51, 6.30] and
18.25 [13.36, 24.86]), and other medical services
visits (8.54 [3.87, 19.92] and 50.20 [16.45,
174.00]; all p\0.05) during the follow-up per-
iod, after adjusting for baseline patient demo-
graphics (Table 2). For both all-cause and
nephropathy-related HRU, the differences in
adjusted annual HRU rates between the albu-
minuria and normoalbuminuria groups
increased with disease severity, with the
macroalbuminuria group exhibiting the highest
HRU in all cases.
Annual All-Cause
and Nephropathy-Related Healthcare
Costs During the Follow-up Period
Patients with microalbuminuria or macroal-
buminuria had significantly higher annual
all-cause healthcare costs (2016 US dollars)
compared to those in the normoalbuminuria
group (mean [SD], normoalbumin-
uria = $12,353 [20,082], microalbuminuria =
$15,893 [29,874], macroalbuminuria =
$25,424 [47,844]), with adjusted cost differ-
ences of $3580 and $12,830 per year, respec-
tively (p\0.05, all comparisons) (Table 3). The
microalbuminuria group had higher costs than
those of the normoalbuminuria group
(p\0.05, all comparisons), and the macroal-
buminuria group had significantly higher
adjusted all-cause healthcare costs than either
the normoalbuminuria or microalbuminuria
groups in all categories (with the exception of
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ER visits in comparison with the microalbu-
minuria group) (Table 3). Inpatient admissions
costs accounted for 45–51% of the adjusted
cost differences between groups, followed by
outpatient (20–24%) and pharmaceutical costs
(10–15%). A similar trend was observed in
adjusted nephropathy-related costs (Table 3).
Compared to patients in the normoalbumin-
uria group, patients with microalbuminuria
and macroalbuminuria incurred higher total
nephropathy-related adjusted healthcare costs,
with increases of $362 and $3716, respectively.
The nephropathy-related total annual health-
care costs among patients with macroalbu-
minuria were $4427, driven by high inpatient
(mean [SD] = $2048 [10,765]) and outpatient
($1526 [11,515]) medical costs.
Fig. 2 Comparison of 1-, 3-, and 5-year clinical outcomes
between groups. a Rates of disease progression: the median
number of follow-up years for the macro-, micro-, and
normoalbuminuria groups was 1.81, 1.93, and 1.95 years,
respectively. The 1-, 3-, and 5-year progression rates for the
macroalbuminuria group were 7.02%, 18.51%, and
31.19%, those for the microalbuminuria group were
5.64%, 13.49%, and 19.19%, and those for the normoal-
buminuria group were 5.26%, 12.25%, and 14.68%.
b Comparison of time to dialysis/hemodialysis: the median
number of follow-up years for the macro-, micro-, and
normoalbuminuria groups was 1.92, 2.06, and 2.13 years,
respectively. The 1-, 3-, and 5-year dialysis rates for the
macroalbuminuria group were 1.75%, 9.46%, and 17.52%,
those for the microalbuminuria group were 0.19%, 0.71%,
and 2.25%, and those for the normoalbuminuria group



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The current study quantifies and underscores
the significant risk of disease progression and
incremental economic burden associated with
microalbuminuria and macroalbuminuria
compared with no renal impairment, as well as
the progressive nature of such outcomes.
The results suggest that the incremental
benefit of treating early-stage diabetic
nephropathy may be substantial. A nearly 50%
increased risk of mortality associated with
albuminuria has been observed with very low
levels not previously believed to be impactful
(15–29 mg/24 h), suggesting an expansion of
the category of diabetic patients who may
benefit from early intervention [22] or screening
[23]. Given the significantly higher risk of
requiring costly dialysis and renal transplanta-
tion procedures in patients with albuminuria,
reducing disease progression rates would result
in significant cost savings. Accordingly, the
development of effective treatments and early
intervention strategies could reduce the risk of
adverse clinical outcomes and ultimately reduce
HRU and costs.
Most importantly, the high disease progres-
sion rates observed in this study, despite the
availability of treatments of diabetic nephropa-
thy, highlight the inadequacy of current DN
treatments and the need for treatments that can
effectively delay disease progression. In 2002,
Adler et al. estimated DN progression rates in a
UK population; progression rates reported in
the current study are higher than those reported
by Adler et al. in particular among patients with
macroalbuminuria [19]. However, our study is
not directly comparable to Adler et al.’s study
for several reasons. Adler et al. defined disease
progression among patients with macroalbu-
minuria by elevated plasma creatinine or renal
replacement therapy [19], and microalbumin-
uria was defined using the UK Prospective Dia-
betes Study standards (urinary albumin
excretion of 50–299 mg/24 h) [24]. In the cur-
rent study, microalbuminuria was defined as
30–300 mg/24 h or an ACR of 30–300 lg/mg,
and macroalbuminuria was defined on the basis






































































































































































































































































































































24 h or ACR of greater than 300 lg/mg. Adler
et al.’s study also classified the stages of diabetic
nephropathy based on two consecutive annual
visits while the current study used only one visit
to define the stages of DN, which might have
resulted in an overestimation of the rates of
progression. Despite these differences, the cur-
rent study provides clinical evidence more
applicable to the US population than Adler
et al.’s study as it was based on the US popula-
tion and had more than four times the number
of included patients. Among other studies con-
ducted within the USA, disease progression rates
are higher than those reported by Adler et al. in
the UK, and more consistent with the findings
of the present study; the Wisconsin Epidemio-
logic Study of Diabetic Retinopathy examined
rates of disease progression among diabetic
patients and reported that during the 15 years
following a diagnosis of diabetes, 45.2% of
patients developed either microalbuminuria or
macroalbuminuria [5].
Disease progression in diabetic nephropathy
has been previously reported to be accompanied
by rising medical treatment costs. Nichols et al.
found that patients with type 2 diabetes and
hypertension who progressed from normal
urine albumin levels to microalbuminuria or
microalbuminuria to macroalbuminuria incur-
red higher incremental annual costs of $2764
and $3618 from pre-progression to post-pro-
gression, respectively [18]. However, that study
focused on a type 2 diabetes population limited
to those with hypertension, which may not be
generalizable to the entire diabetic nephropathy
population, and costs were imputed using
‘‘standard’’ unit costs for visit types and visits
frequencies rather than actual costs incurred.
Conversely, the current study included a
broadly defined population—any patients with
type 2 diabetes—and compared both the fre-
quency of healthcare visits and actual incurred
healthcare costs between patients with and
without nephropathy, as well as between
patients with macroalbuminuria versus
microalbuminuria. We found that, consistent
with worsening clinical outcomes, patients with
microalbuminuria and macroalbuminuria had
higher all-cause and nephrology-related HRU
and a substantial economic burden. However,
the adjusted incremental all-cause cost burdens
associated with macroalbuminuria as compared
to microalbuminuria (an adjusted difference of
$9250) or patients without albuminuria
($12,830), as well as that of microalbuminuria
compared with patients without albuminuria
($3580), were higher than those found by
Nichols et al. This difference may be due to
differing levels of disease progression during
follow-up between the two studies; only 5% of
patients with macroalbuminuria were observed
to progress to ESRD in Nichols et al. [18] (over
6.5 years of follow-up), compared to the esti-
mated 5-year progression rate of 31% in the
current study. Additionally, the current study
observed higher annual costs at baseline among
the normoalbuminuria, microalbuminuria, and
macroalbuminuria groups, which may be
indicative of underlying differences in cost cal-
culations compared to that study.
This study also demonstrated that despite
abnormal urine albumin test results, many
patients are not receiving treatment for diabetic
nephropathy—between 12% and 20% remained
untreated during the 6 months following an
abnormal urine albumin test result. However,
among those treated, less than half of patients
used ACE inhibitors or ARBs, the current treat-
ments recommended by the American Diabetes
Association (ADA) for patients with elevated
urinary albumin excretion [8]. The results of
this study have additional important implica-
tions for physicians treating patients with
type 2 diabetes as well as for payers as it
demonstrates the possible undertreatment and
inappropriate treatment of patients with DN.
Given the incremental benefit of treating ear-
ly-stage diabetic nephropathy, both DN diag-
nosis and appropriate treatment must be timely
as they are critical for delaying disease progres-
sion and reducing healthcare costs.
This study was subject to certain limitations.
Patients were required to be continuously
enrolled for at least 6 months after the index
date and until the follow-up urine albumin test,
which may introduce immortal time bias.
However, as the mean follow-up time was sim-
ilar among groups (1.69 years for the normoal-
buminuria group, 1.67 years for the
microalbuminuria group, and 1.63 years for the
Diabetes Ther
macroalbuminuria group) the impact of this
bias is expected to be similar across groups;
thus, the results would be expected to be qual-
itatively similar to the results if immortal time
bias was completely eliminated. The use of a
single urine albumin test to determine
increased urinary albumin excretion rates may
cause misclassification of disease progression; if
the urine albumin was transiently elevated, an
underestimation of the difference between
groups may have occurred.
Although the database is geographically
representative of the USA, the data included
only commercially insured patients and those
who have commercial insurance in supplement
to Medicare. In addition, to evaluate disease
progression of diabetic nephropathy, the cur-
rent study sample was further restricted to the
subset of patients who were also in the Mar-
ketScan Lab Database and who had two urine
albumin tests results. Thus, the results may not
be generalizable across all study populations.
The selection of patients with two urine
albumin tests for inclusion in the study may
bias the study population toward one at high
risk for diabetic nephropathy, who requires
frequent monitoring of urine albumin levels,
thus potentially biasing the study results toward
greater progression rates than those of the
general type 2 diabetic population. However,
because the study results are consistent with a
US prospective study, the selection bias is min-
imized. Furthermore, the limited information
available in the database prevented further
analysis on important patient characteristics
(e.g., diabetes disease duration since the initial
diagnosis, race), indirect costs (e.g., lost pro-
ductivity), and additional important clinical
measures (e.g., HbA1c, eGFR).
CONCLUSION
Microalbuminuria and macroalbuminuria were
associated with significantly higher risk of dis-
ease progression and substantially increased
economic burden among commercially insured
patients with type 2 diabetes in the USA. These
results highlight the persisting unmet need for
effective treatments and early intervention
strategies for adult patients with diabetic
nephropathy.
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